Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
Covered by 3 sources from 2 countries. First reported by MarketWatch ·
Headlines compared
Common ground: most headlines mention “GLP”.
Different angles:
- MarketWatch “Ozempic Zepbound and other”
- The Guardian “Pharma firms focus on weight”
How 3 newspapers cover this story
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned…
What to know about new GLP-1 warning on possible vision loss
Dr. Jon LaPook joins "CBS Mornings" to break down the facts on a new warning about GLP-1 medications causing possible vision loss.
Coverage details
3 outlets from 2 countries are covering this story: MarketWatch, The Guardian and CBS News. MarketWatch published it first, on November 9, 2026; the last outlet to join was CBS News, 20 hours later.
Key names in the coverage: Jon LaPook, CBS Mornings, Zepbound and NAION.
By country: United States (2), United Kingdom (1).
